BRPI0921230A2 - agonistas de receptor de neuropeptídeos-2 (y-2r) e usos dos mesmo. - Google Patents

agonistas de receptor de neuropeptídeos-2 (y-2r) e usos dos mesmo.

Info

Publication number
BRPI0921230A2
BRPI0921230A2 BRPI0921230A BRPI0921230A BRPI0921230A2 BR PI0921230 A2 BRPI0921230 A2 BR PI0921230A2 BR PI0921230 A BRPI0921230 A BR PI0921230A BR PI0921230 A BRPI0921230 A BR PI0921230A BR PI0921230 A2 BRPI0921230 A2 BR PI0921230A2
Authority
BR
Brazil
Prior art keywords
neuropeptide
receptor agonists
agonists
receptor
Prior art date
Application number
BRPI0921230A
Other languages
English (en)
Inventor
C Fry David
Wright Tilley Jefferson
Swistok Joseph
Fotouhi Nader
Khan Wajiha
Danho Waleed
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0921230A2 publication Critical patent/BRPI0921230A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2271—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0921230A 2008-11-05 2009-10-26 agonistas de receptor de neuropeptídeos-2 (y-2r) e usos dos mesmo. BRPI0921230A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11144208P 2008-11-05 2008-11-05
PCT/EP2009/064034 WO2010052144A2 (en) 2008-11-05 2009-10-26 Neuropeptide-2-receptor (y-2r) agonists and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0921230A2 true BRPI0921230A2 (pt) 2018-10-30

Family

ID=42077641

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0921230A BRPI0921230A2 (pt) 2008-11-05 2009-10-26 agonistas de receptor de neuropeptídeos-2 (y-2r) e usos dos mesmo.

Country Status (11)

Country Link
US (1) US20100179093A1 (pt)
EP (1) EP2352511A2 (pt)
JP (1) JP2012507487A (pt)
KR (1) KR20110097807A (pt)
CN (1) CN102202681A (pt)
AU (1) AU2009312892A1 (pt)
BR (1) BRPI0921230A2 (pt)
CA (1) CA2741921A1 (pt)
IL (1) IL212364A0 (pt)
MX (1) MX2011004427A (pt)
WO (1) WO2010052144A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9260500B2 (en) 2009-07-02 2016-02-16 Takeda Pharmaceutical Company Limited Peptide and use thereof
CA2776302A1 (en) * 2009-10-13 2011-04-21 F. Hoffmann-La Roche Ag Neuropeptide-2 receptor (y-2r) agonists
DK3326620T3 (da) 2010-12-16 2020-05-25 Novo Nordisk As Faste sammensætninger omfattende en glp-1-agonist og et salt af n-(8-(2- hydroxybenzoyl)amino)caprylsyre
AU2013234496B2 (en) 2012-03-22 2017-07-27 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
GB201315335D0 (en) * 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
EP3068421B1 (en) 2013-11-15 2019-04-17 Novo Nordisk A/S Selective pyy compounds and uses thereof
EP3068795B1 (en) 2013-11-15 2019-03-06 Novo Nordisk A/S Hpyy(1-36) having a beta-homoarginine substitution at position 35
US10588980B2 (en) * 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
TWI694082B (zh) 2015-06-12 2020-05-21 丹麥商諾佛 儂迪克股份有限公司 選擇性ｐｙｙ化合物及其用途
JOP20190097A1 (ar) * 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv الجلوبولينات المناعية واستخداماتها
ES2960687T3 (es) 2018-02-02 2024-03-06 Novo Nordisk As Composiciones sólidas que comprenden un agonista del GLP-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico y un lubricante

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US6013633A (en) * 1997-08-07 2000-01-11 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
US7410949B2 (en) * 2005-01-18 2008-08-12 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
EP1858545A2 (en) * 2005-03-04 2007-11-28 Curedm Inc. Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
NZ568772A (en) * 2005-12-07 2010-05-28 Hoffmann La Roche Truncated analogs of the peptide pYY3-36 that are neuropeptide-2 receptor-agonists

Also Published As

Publication number Publication date
JP2012507487A (ja) 2012-03-29
MX2011004427A (es) 2011-05-31
CA2741921A1 (en) 2010-05-14
EP2352511A2 (en) 2011-08-10
IL212364A0 (en) 2011-06-30
WO2010052144A3 (en) 2010-07-08
CN102202681A (zh) 2011-09-28
AU2009312892A1 (en) 2010-05-14
WO2010052144A2 (en) 2010-05-14
KR20110097807A (ko) 2011-08-31
US20100179093A1 (en) 2010-07-15

Similar Documents

Publication Publication Date Title
BRPI0921230A2 (pt) agonistas de receptor de neuropeptídeos-2 (y-2r) e usos dos mesmo.
BRPI0922483A2 (pt) agonista de receptor gpr120 e usos dos mesmos
BRPI0914891A2 (pt) agonistas de aril gpr119 e usos dos mesmos
BRPI0918868A2 (pt) moduladores do receptor de nmda e usos dos mesmos
BRPI0918652A2 (pt) Composições farmacêuticas e métodos de libração relacionadas.
BRPI0920927A2 (pt) derivados de azaquinolinona e usos dos mesmos
BRPI0912198A2 (pt) anticorpos anti-fn14 e usos dos mesmos
BRPI1013943A2 (pt) Composto cetais e usos dos mesmos.
BRPI0918122A2 (pt) molécula de diaboy, diaboy, e mólecula dart
BRPI0917358A2 (pt) formulação farmacêutica de liberação controlada e método.
BRPI0920209A2 (pt) conjugados de agonistas de glp-1 e usos dos mesmos
BRPI0920962A2 (pt) variantes de polipeptídeos receptores de activina iib e usos dos mesmos
FR2934188B1 (fr) Dispositif de serrage
BRPI0915142A2 (pt) polipeptídeos, ácido nucleico e usos dos mesmos
BRPI0920406A2 (pt) dispositivos de terminação e métodos relacionados.
BRPI0915433A2 (pt) método, e, dispositivo.
BRPI0818477A2 (pt) Dc-sign, icam-3 e lsectin porcinos e usos dos mesmos
BRPI0918502A2 (pt) aminoindanos substituídos e análogos dos mesmos, e o uso farmacêutico dos mesmos
BRPI0912615A2 (pt) agonistas de receptor y2 e/ou y4 de longa ação
BRPI0822337A2 (pt) Folatos, composições e usos dos mesmos
BRPI0920953A2 (pt) dispositivo de manutenção, e uso do mesmo.
BRPI0807911A2 (pt) Agonistas de alfa2c adrenorreceptor
BRPI0913188A2 (pt) moduladores de receptores 5-ht3, métodos de fabricação, e uso dos mesmos
BRPI0921997A2 (pt) dispositivo para medição do componente de sangue.
FR2935737B1 (fr) Dispositif de cogeneration amelioree

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2497 DE 13-11-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.